Comparison of causes and manifestations of pain in Parkinson’s disease patients to healthy controls

Objective To assess the manifestations of pain in PD (Parkinson’s disease ) patients versus healthy controls.Methods Data on pain was collected from 127 patients and an equivalent number of controls using two self-report questionnaires: the Brief Pain Inventory (BPI) and a custom-made questionnaire focusing on specific details not covered by the former. Additional analysis was conducted within the patient group only to analyze the potential effects of factors relating to PD on the various measure of interest relating to pain.Results Parkinson disease patients had lower odds of experiencing pain in both arms (ExpB=0.061, p<0.001), greater probability of demonstrating pain in both legs (ExpB=2.409, p=0.024), and an increase difficulty in localizing pain (ExpB=2.958, p=0.030). There was no relationship between duration of pain (F=12.414, p=0.001) or arthritis (ExpB=0.724, p=0.309) and pain in PD. The likelihood of experiencing nagging pain (ExpB=3.533, p=0.028), but not other forms, was much more strongly associated with PD patients than normal controls. When all other types of pain were controlled for, pain in PD is more likely associated with akathesic pain (ExpB=9.046, p<0.001).Conclusion There are major differences between pain in PD patients and pain in normal controls, which could have implications on the pathophysiology and adequate management of pain in different populations.Key words: Healthy controls, movement disorders, pain, Parkinson’s diseas

Yield Performances and Cup Quality of Some BTRI Test Clones of Tea

A long term experiment was conducted to investigate the yield and quality performances of four vegetative propagated test clones of tea coded as A/8/01, A/17/22, A/22/27 and A/22/40 at Bangladesh Tea Research Institute (BTRI) farm during 1996-2010. A standard clone BT1 was considered as control. Cuttings of the test clones were collected from the selected bushes of Amo tea estates and were raised at BTRI nursery. Then saplings were put to long term yield and quality trial following Latin Square Design (LSD) with 3 replications. The green leaf was harvested at weekly interval during the plucking season starting from mid March to mid December throughout the experimental period. Yield data were recorded and analyzed statistically using MSTAT programme. Results of the experiment revealed that among the test clones A/22/40 gave the highest significant yield of 3509.1 kg ha-1 of made tea followed by BT1 (3203.69 kg ha-1), A/8/01 (2912.24 kg ha-1), A/17/22 (2817.76 kg ha-1) and A/22/27 (2278.78 kg ha-1) from the average of 9 years (2002-2010) at mature stage. At immature stage i.e. 1st year to 5th year after plantation yield difference was insignificant. The overall cup quality of the test clones was assessed by conventional organoleptic test. The cup quality of A/8/01, A/17/22, A/22/40 as well as the standard clone BT1 was found to be above average (AA) while the cup quality of A/22/27 was average (A). Considering the yield and quality potentials, the test clone A/22/40 has appeared quite promising to be released as a standard clone. DOI: http://dx.doi.org/10.3329/ijarit.v1i1-2.13925 Int. J. Agril. Res. Innov. & Tech. 1 (1&2): 24-28, December, 201

Abdominal Pain: a Symptom of Levodopa End of Dose Wearing off in Parkinson’s Disease

Long-term levodopa use is associated with the “End of Dose Wearing Off” (EODWO) phenomenon wherein Parkinsonian symptoms return before a patient’s next scheduled dose of levodopa. Wearing off symptoms may include a variety of autonomic, emotional, motor, psychological and sensory abnorma-lities. Abdominal pain may be an important wearing off symptom as an early indicator of the development of EODWO in Parkinson’s disease (PD) patients. In this report, we present two patients on levodopa therapy for PD who developed acute abdominal pain as a symptom of EODWO. Keywords: Abdominal, levodopa "Dolor abdominal – un síntoma de deterioro de fin de dosis de levodopa en la enfermedad de Parkinson" RESUMEN El uso de levodopa a largo plazo está asociado con el fenómeno conocido como “deterioro de fin de dosis” (en inglés, EODWO), en el que los síntomas parkinsonianos regresan antes de la siguiente dosis de levodopa programada para un paciente. El deterioro de los síntomas puede incluir una variedad de anomalías autonómicas, emocionales, psicológicas, motoras y sensoriales. El dolor abdominal puede ser un importante síntoma de “wearing off” o deterioro de fin de dosis, que constituye un indicador temprano del desarrollo de EODWO en los pacientes de la enfermedad de Parkinson (EP). En este informe, presentamos dos pacientes bajo tratamiento con levodopa para la EP, que desarrollaron dolor abdominal agudo como un síntoma de EODWO. Palabras claves: Abdominalgia, levodop

New and emerging treatments for symptomatic tardive dyskinesia

Abdul Qayyum Rana,1–4 Zishan M Chaudry,5 Pierre J Blanchet6 1Parkinson's Clinic of Eastern Toronto and Movement Disorders Centre, Toronto, ON, Canada; 2Scarborough Memory Program, Toronto, ON, Canada; 3Journal of Parkinsonism and RLS, Toronto, ON, Canada; 4Bulletin of World Parkinson's Program, Toronto, ON, Canada; 5Saba University School of Medicine, The Bottom, Saba, Dutch Caribbean; 6Department of Stomatology, University of Montreal, Montreal, QC, Canada Abstract: The aim of this review is to assess new, emerging, and experimental treatment options for tardive dyskinesia (TD). The methods to obtain relevant studies for review included a MEDLINE search and a review of studies in English, along with checking reference lists of articles. The leading explanatory models of TD development include dopamine receptor supersensitivity, GABA depletion, cholinergic deficiency, neurotoxicity, oxidative stress, changes in synaptic plasticity, and defective neuroadaptive signaling. As such, a wide range of treatment options are available. To provide a complete summary of choices we review atypical antipsychotics along with resveratrol, botulinum toxin, Ginkgo biloba, tetrabenazine, clonazepam, melatonin, essential fatty acids, zonisamide, levetiracetam, branched-chain amino acids, drug combinations, and invasive surgical treatments. There is currently no US Food and Drug Administration-approved treatment for TD; however, prudent use of atypical antipsychotics with routine monitoring remain the cornerstone of therapy, with experimental treatment options available for further management. Keywords: tardive dyskinesia, first-generation antipsychotics, motor symptoms, schizophrenia, Parkinson's, atypical antipsychotic